<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315627</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0205</org_study_id>
    <nct_id>NCT00315627</nct_id>
  </id_info>
  <brief_title>Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation</brief_title>
  <official_title>Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rodolfo Alejandro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:

        1. To reverse hyperglycemia and insulin dependency in patients with type 1 diabetes
           mellitus through islet transplantation utilizing steroid free, calcineurin-inhibitor
           free immunosuppression.

        2. To assess the long-term function of successful islet transplants in patients with type 1
           diabetes mellitus utilizing islets that have undergone a period of culture.

        3. To determine whether the natural history of the microvascular, macrovascular, and
           neuropathic complications are altered following the successful transplantation of
           islets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN:

      The initial proposal submitted to the JDRFI was to compare 3 different groups of patients
      receiving islet cell transplants utilizing steroid-free, calcineurin-free protocols. The 3
      groups were as follows:

        1. Zenapax, Rapamycin &amp; MMF

        2. Campath, Rapamycin &amp; MMF, and

        3. Thymoglobulin, Rapamycin &amp; MMF.

      The grant was awarded in December 2003, however the recommendations were to focus on a single
      group (group 3 or 4) in order to determine the relative efficacy and toxicity of a new
      immunosuppressive drug combination. We elected to perform the group utilizing Campath, since
      we have a similar protocol utilizing the same immunosuppressive regimen with the addition of
      CD34+ enriched donor bone marrow cells (2000/0024). The results of this trial utilizing a
      steroid-free/calcineurin-free protocol will be compared with the standard &quot;Edmonton Protocol&quot;
      (2000/0196), which we are currently conducting (14 patients have been transplanted). In
      addition, the results will be compared with those in 2000/0024.

      Protocol 2000/0024 (utilizing the same immunosuppressive regimen; Campath, Rapamycin,
      Tacrolimus-switched to MMF at 3 months) is being followed by a DSMB established at the NIH.

      We propose to evaluate 12 patients with steroid free, long term calcineurin inhibitor free
      immunosuppression regimens which can be directly compared to our historical group of patients
      who underwent the Miami version of the Edmonton protocol (Islet Cell Transplantation Alone in
      Patients with Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression - Protocol # 2000/196)
      and with the concurrent tolerogenic protocol (Islet Cell Transplantation Alone and CD34+
      Enriched Donor Bone Marrow Cell Infusion in Patients with Type 1 Diabetes Mellitus; Steroid
      Free Regimen - Protocol # 2000/0024) which uses the same immunosuppressive regimen combined
      with CD34+ stem cell enriched donor bone marrow infusions.

      The regimen will consist of Campath 1-H induction, maintenance immunosuppression with
      sirolimus and tacrolimus for 3 months with subsequent introduction of mycophenolate mofetil
      (MMF) and removal of tacrolimus completely and TNF-alpha inhibition (etanercept) in the
      peri-transplant period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects at 1 year with HbA1c &lt; 6.5% and absence of severe hypoglycemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Islet Allograft Function</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects with basal C-peptide greater than 0.5 ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Metabolic Control as Evidenced by Hemoglobin A1c &lt; 6.5%</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects with a hemoglobin A1c &lt; 6.5% at 1year after islet transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination of Severe Hypoglycemia</measure>
    <time_frame>1 year</time_frame>
    <description>The number of subjects with severe hypoglycemia after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restoration of Hypoglycemia Awareness 1 Year After Transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>The number of subjects with restoration of hypoglycemia awareness 1 year after islet transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>islet transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Islet Alone Transplantation under Alentuzumab (Campath1H) induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Islet transplantation</intervention_name>
    <description>Islet transplantation</description>
    <arm_group_label>islet transplantation</arm_group_label>
    <other_name>islet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Potential candidates must have type 1 diabetes mellitus and fulfill one or more of the
        following:

          1. Manifest signs and symptoms that are severe enough to be incapacitating.
             Incapacitating signs and symptoms include hypoglycemic episodes requiring assistance
             by others and hypoglycemia unawareness (the inability to recognize low blood glucoses;
             glucoses &lt; 54 mg/dl). These patients are at high risk for involvement in accidents
             (they can lose consciousness or act irrationally), thus causing harm to themselves
             and/or others.

          2. Patients with poor diabetes control (HbA1c &gt; 8.0% but &lt; 12%), despite intensive
             insulin therapy, as defined by: self monitoring of blood glucose ≥ 4 times/day,
             multiple insulin injections (≥ 3/day) or insulin pump, and close monitoring of blood
             glucose control by an endocrinologist. These patients can experience acute, rapid
             hyperglycemia secondary to several stress factors, that can lead to dehydration,
             disorientation, and in some instances, ketoacidosis.

          3. Progressive diabetic complications. These patients with chronically poor glycemic
             control are at higher risk for the development of a wide variety of complications
             (retinopathy, neuropathy, nephropathy, and cardiovascular disease) associated with
             diabetes.

        Exclusion Criteria:

        Potential candidates will be excluded as per the following criteria:

          1. Age &lt; 18 or &gt; 65 years

          2. Duration of diabetes &lt; 5 years

          3. Do not have a physician that is monitoring diabetes for &gt; 6 months

          4. Body mass index &gt; 26

          5. Weight &gt; 80 kg

          6. Insulin requirement &gt; 1.0 u/kg/d

          7. HbA1c &gt; 12%

          8. Stimulated or basal C-peptide &gt; 0.3 ng/ml

          9. Corrected creatinine clearance &lt; 60 ml/min

         10. Serum creatinine consistently above 1.6 mg/dl

         11. Macroalbuminuria (&gt; 300 mg/24 hours)

         12. Anemia (hemoglobin &lt; 12.0 g/dl for males; &lt; 11 g/dl for females)

         13. Hyperlipidemia (fasting low-density lipoprotein [LDL] cholesterol &gt; 130 mg/dl and/or
             fasting triglycerides &gt; 200 mg/dl)

         14. Abnormal liver function tests (consistently &gt; 1.5 x normal range)

         15. Serological evidence of HIV, HBsAg and/or HBcAb, HBsAb without history of vaccination,
             human t cell lymphotropic virus 1 (HTLV-1), or hepatitis C virus (HCV)

         16. Negative serology for Epstein-Barr virus (EBV) or evidence of acute or chronic
             infection (IgM ≥ IgG)

         17. Lack of updated immunizations per current Centers for Disease Control (CDC) guidelines
             (including lack of immunization against hepatitis B, pneumococcus and influenza -
             during season)

         18. Presence of panel reactive antibodies &gt; 20%

         19. Prostate-specific antigen (PSA) &gt; 4 ng/ml unless malignancy is ruled out

         20. Positive tuberculin test (unless proof of adequate treatment for latent tuberculosis
             can be provided)

         21. X-ray evidence of pulmonary infection or other significant pathology

         22. Gall stones and/or portal hypertension and/or hemangioma on liver ultrasound

         23. Abnormal abdominal or pelvic ultrasound (evidence of masses that are considered
             suspicious for malignancy or adenopathy)

         24. Active peptic ulcer disease

         25. Active infections

         26. Unstable cardiovascular status (including positive stress echocardiography if age &gt;
             35)

         27. Untreated or unstable proliferative diabetic retinopathy

         28. Previous/concurrent organ transplantation (except for failed islet cell or pancreas
             transplantation)

         29. Malignancy or previous malignancy

         30. Any medical condition requiring chronic use of steroids

         31. Active alcohol or substance abuse; smoking in the last 6 months.

         32. Sexually active females who are not:

               -  post-menopausal,

               -  surgically sterile, or

               -  not using an acceptable method of contraception (oral contraceptives, Norplant,
                  Depo-Provera, and barrier devices with spermicide are acceptable; condoms used
                  alone are not acceptable)

         33. Positive pregnancy test or intent for future pregnancy, or male subject's intent to
             procreate

         34. Any condition or any circumstances that make it unsafe to undergo an islet cell
             transplant

         35. Psychogenically unable to comply

         36. Failed psychological evaluation

         37. Persistent leukopenia (white blood cell count &lt; 3,000/uL on more than 3 occasions)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Alejandro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Research Institute - University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.diabetesresearch.org</url>
    <description>Diabetes Research Institute web site</description>
  </link>
  <results_reference>
    <citation>Froud T, Baidal DA, Faradji R, Cure P, Mineo D, Selvaggi G, Kenyon NS, Ricordi C, Alejandro R. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Transplantation. 2008 Dec 27;86(12):1695-701. doi: 10.1097/TP.0b013e31819025e5.</citation>
    <PMID>19104407</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2006</study_first_submitted>
  <study_first_submitted_qc>April 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2006</study_first_posted>
  <results_first_submitted>December 19, 2016</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Rodolfo Alejandro</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Islet Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Islet Transplantation</title>
          <description>Single arm study. Subjects with Type 1 Diabetes, severe hypoglycemia and hypoglycemia unawareness received intrahepatic islet transplantation (1 or 2 infusions) under alemtuzumab induction and rapamycin + MMF maintenance immunosuppression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Islet Transplantation</title>
          <description>Islet transplantation: Islet transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia</title>
        <description>Number of subjects at 1 year with HbA1c &lt; 6.5% and absence of severe hypoglycemia</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplantation</title>
            <description>Single arm study. Subjects with Type 1 Diabetes, severe hypoglycemia and hypoglycemia unawareness received intrahepatic islet transplantation (1 or 2 infusions) under alemtuzumab induction and rapamycin + MMF maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia</title>
          <description>Number of subjects at 1 year with HbA1c &lt; 6.5% and absence of severe hypoglycemia</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Islet Allograft Function</title>
        <description>Number of subjects with basal C-peptide greater than 0.5 ng/ml</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplantation</title>
            <description>Islet Alone Transplantation under Alentuzumab (Campath1H) induction.</description>
          </group>
        </group_list>
        <measure>
          <title>Islet Allograft Function</title>
          <description>Number of subjects with basal C-peptide greater than 0.5 ng/ml</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Metabolic Control as Evidenced by Hemoglobin A1c &lt; 6.5%</title>
        <description>Number of subjects with a hemoglobin A1c &lt; 6.5% at 1year after islet transplantation</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplantation</title>
            <description>Islet Alone Transplantation under Alentuzumab (Campath1H) induction.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Metabolic Control as Evidenced by Hemoglobin A1c &lt; 6.5%</title>
          <description>Number of subjects with a hemoglobin A1c &lt; 6.5% at 1year after islet transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination of Severe Hypoglycemia</title>
        <description>The number of subjects with severe hypoglycemia after transplantation</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplantation</title>
            <description>Islet Alone Transplantation under Alentuzumab (Campath1H) induction.
Islet transplantation: Islet transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination of Severe Hypoglycemia</title>
          <description>The number of subjects with severe hypoglycemia after transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Restoration of Hypoglycemia Awareness 1 Year After Transplantation</title>
        <description>The number of subjects with restoration of hypoglycemia awareness 1 year after islet transplantation</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplantation</title>
            <description>Single arm study. Subjects with Type 1 Diabetes, severe hypoglycemia and hypoglycemia unawareness received intrahepatic islet transplantation (1 or 2 infusions) under alemtuzumab induction and rapamycin + MMF maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Restoration of Hypoglycemia Awareness 1 Year After Transplantation</title>
          <description>The number of subjects with restoration of hypoglycemia awareness 1 year after islet transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Islet Transplantation</title>
          <description>Islet transplantation alone under alentuzumab (Campath1H) induction.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <description>lymphopenia secondary to t-cell depletion with alentuzumab (Campath1H)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <description>chest pain, back pain, abdominal pain with nausea and vomiting after administration of IV iron (Ferrlecit; sodium ferric gluconate) for anemia.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Capsular opacity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gallblader polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pulpitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right foot injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Toe sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Memory deficit</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Overt Proteinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Yeast infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Uterine fibroids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abnormal Papsmear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rinorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Displastic Nevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Acne/Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis Right arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rodolfo Alejandro</name_or_title>
      <organization>University of Miami Miller School of Medicine</organization>
      <phone>305 243-5324</phone>
      <email>ralejand@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

